Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. September 2018 16:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Provides Corporate and Clinical Update

- Webcast and conference call for investors and analystson Thursday, September 20 at 8:30 a.m. EDT - CALGARY, Alberta and SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc....
17. September 2018 07:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care

CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
10. September 2018 07:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

CALGARY, Alberta and SAN DIEGO, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
06. September 2018 07:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program

CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
03. August 2018 07:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Reports 2018 Second Quarter Results

CALGARY, Alberta and SAN DIEGO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
31. Juli 2018 07:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference

CALGARY, Alberta and SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
05. Juni 2018 12:49 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares

CALGARY, Alberta and SAN DIEGO, June 05, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
04. Juni 2018 09:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting

CALGARY, Alberta and SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
01. Juni 2018 09:13 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares

CALGARY, Alberta and SAN DIEGO, June 01, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
01. Juni 2018 07:40 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Listing on Nasdaq Capital Market

CALGARY, Alberta and SAN DIEGO, June 01, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...

Vorherige Seite

Nächste Seite